$AIM
AIM ImmunoTech Inc. Stock $aim

$aim Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223028610 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$46.00K	$42.00K	$30.00K
YoY Change	119.05%	40.0%	30.43%
Cost Of Revenue	$30.00K	$0.00	$69.00K
YoY Change		-100.0%	-86.65%
Gross Profit	$16.00K	$42.00K	-$39.00K
YoY Change	-23.81%	-207.69%	-91.61%
Gross Profit Margin	34.78%	100.0%	-130.0%
Selling, General & Admin	$5.439M	$2.550M	$2.181M
YoY Change	5.2%	16.92%	-48.75%
% of Gross Profit	33993.75%	6071.43%
Research & Development	$2.734M	$2.953M	$2.475M
YoY Change	99.27%	19.31%	87.93%
% of Gross Profit	17087.5%	7030.95%
Depreciation & Amortization	$53.00K	$80.00K	$29.00K
YoY Change	89.29%	175.86%	-83.71%
% of Gross Profit	331.25%	190.48%
Operating Expenses	$2.734M	$2.953M	$2.475M
YoY Change	99.27%	19.31%	87.93%
Operating Profit	-$8.157M	-$5.461M	-$4.695M
YoY Change	25.09%	16.32%	26.28%
Interest Expense	-$16.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$294.0K	$318.0K	$3.000K
YoY Change	70.93%	10500.0%	-110.34%
Pretax Income	-$7.816M	-$4.909M	-$4.851M
YoY Change	22.41%	1.2%	-48.69%
Income Tax
% Of Pretax Income
Net Earnings	-$7.816M	-$4.909M	-$4.851M
YoY Change	22.41%	1.2%	-17.44%
Net Earnings / Revenue	-16991.3%	-11688.1%	-16170.0%
Basic Earnings Per Share	-$0.16	-$0.10	-$0.10
Diluted Earnings Per Share	-$0.16	-$0.10	-$101.0K
COMMON SHARES
Basic Shares Outstanding	48.67M shares	48.41M shares
Diluted Shares Outstanding	48.64M shares	48.41M shares	48.03M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.43M	$28.40M	$41.77M
YoY Change	-38.95%	-32.02%	1.53%
Cash & Equivalents	$15.26M	$21.04M	$34.45M
Short-Term Investments	$7.167M	$7.360M	$7.320M
Other Short-Term Assets	$263.0K	$438.0K	$4.273M
YoY Change	-94.03%	-89.75%	2656.77%
Inventory
Prepaid Expenses
Receivables	$48.00K	$33.00K	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$22.74M	$28.87M	$46.05M
YoY Change	-44.73%	-37.3%	11.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$136.0K	$145.0K	$127.0K
YoY Change	15.25%	14.17%	-97.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.102M	$1.784M	$1.811M
YoY Change	-1.68%	-1.49%	53.87%
Total Long-Term Assets	$5.119M	$4.748M	$4.839M
YoY Change	-0.31%	-1.88%	-80.95%
TOTAL ASSETS
Total Short-Term Assets	$22.74M	$28.87M	$46.05M
Total Long-Term Assets	$5.119M	$4.748M	$4.839M
Total Assets	$27.86M	$33.62M	$50.88M
YoY Change	-39.81%	-33.93%	-23.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.788M	$2.151M	$712.0K
YoY Change	191.33%	202.11%	57.87%
Accrued Expenses	$1.721M	$528.0K	$502.0K
YoY Change	-2.6%	5.18%	18.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.716M	$2.885M	$1.368M
YoY Change	62.9%	110.89%	56.16%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$543.0K	$597.0K	$736.0K
YoY Change	-21.87%	-18.89%	134.39%
Total Long-Term Liabilities	$543.0K	$597.0K	$736.0K
YoY Change	-21.87%	-18.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.716M	$2.885M	$1.368M
Total Long-Term Liabilities	$543.0K	$597.0K	$736.0K
Total Liabilities	$5.259M	$3.482M	$2.104M
YoY Change	46.49%	65.49%	76.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$396.9M	-$389.1M	-$369.8M
YoY Change	5.52%	5.23%
Common Stock	$48.00K	$48.00K	$417.8M
YoY Change	0.0%	-99.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$22.60M	$30.14M	$48.78M
YoY Change
Total Liabilities & Shareholders Equity	$27.86M	$33.62M	$50.88M
YoY Change	-39.81%	-33.93%	-23.74%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$7.816M	-$4.909M	-$4.851M
YoY Change	22.41%	1.2%	-17.44%
Depreciation, Depletion And Amortization	$53.00K	$80.00K	$29.00K
YoY Change	89.29%	175.86%	-83.71%
Cash From Operating Activities	-$5.671M	-$2.158M	-$2.313M
YoY Change	14.15%	-6.7%	34.63%
INVESTING ACTIVITIES
Capital Expenditures	$184.0K	$203.0K	-$43.00K
YoY Change	-1020.0%	-572.09%	65.38%
Acquisitions
YoY Change
Other Investing Activities	-$152.0K	-$1.000K	$7.764M
YoY Change	-156.3%	-100.01%	-789.52%
Cash From Investing Activities	-$336.0K	-$204.0K	$7.721M
YoY Change	-234.4%	-102.64%	-770.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	233.0K	5.000K	55.00K
YoY Change	832.0%	-90.91%	-101.16%
NET CHANGE
Cash From Operating Activities	-5.671M	-2.158M	-2.313M
Cash From Investing Activities	-336.0K	-204.0K	7.721M
Cash From Financing Activities	233.0K	5.000K	55.00K
Net Change In Cash	-5.774M	-2.357M	5.463M
YoY Change	23.03%	-143.14%	-171.59%
FREE CASH FLOW
Cash From Operating Activities	-$5.671M	-$2.158M	-$2.313M
Capital Expenditures	$184.0K	$203.0K	-$43.00K
Free Cash Flow	-$5.855M	-$2.361M	-$2.270M
YoY Change	18.33%	4.01%	34.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000946644
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q2	us-gaap	Manufacturing Costs ManufacturingCosts		usd
	us-gaap	Manufacturing Costs ManufacturingCosts		usd
CY2023Q2	us-gaap	Interest Expense InterestExpense		usd
CY2022Q2	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Interest Expense InterestExpense		usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2022Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	AIM	Proceeds From Payments To Purchase Of Property And Equipment ProceedsFromPaymentsToPurchaseOfPropertyAndEquipment		usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities		usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Entity File Number EntityFileNumber	001-27072
	dei	Entity Registrant Name EntityRegistrantName	AIM IMMUNOTECH INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-0845822
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2117 SW Highway 484
	dei	Entity Address City Or Town EntityAddressCityOrTown	Ocala
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34473
	dei	City Area Code CityAreaCode	(352)
	dei	Local Phone Number LocalPhoneNumber	448-7797
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	AIM
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48670427	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21038000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27053000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7360000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7137000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1676000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	438000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	455000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	28869000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	36321000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	145000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	195000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	781000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	829000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2038000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1941000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1784000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1202000	usd
CY2023Q2	us-gaap	Assets Assets	33617000	usd
CY2022Q4	us-gaap	Assets Assets	40488000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2151000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	377000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	528000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	806000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	206000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	178000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2885000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1361000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	597000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	659000	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	690000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	696000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48419491	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48419491	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48084287	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48084287	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	48000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	48000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	418513000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	418270000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-389116000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-380546000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30135000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33617000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40488000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	42000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	91000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64000	usd
CY2023Q2	us-gaap	Revenues Revenues	42000	usd
CY2022Q2	us-gaap	Revenues Revenues	30000	usd
	us-gaap	Revenues Revenues	91000	usd
	us-gaap	Revenues Revenues	64000	usd
CY2022Q2	us-gaap	Manufacturing Costs ManufacturingCosts	69000	usd
	us-gaap	Manufacturing Costs ManufacturingCosts	147000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2953000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2475000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5005000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3511000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2550000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2181000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4841000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4253000	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	5503000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	4725000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	9846000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	7911000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5461000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4695000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9755000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7847000	usd
CY2023Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-94000	usd
CY2022Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-470000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	109000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1404000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	318000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	79000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	517000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	124000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-23000	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-34000	usd
CY2023Q2	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-328000	usd
CY2022Q2	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-232000	usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-582000	usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-422000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4909000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4851000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8570000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8671000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2023Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48411251	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48411251	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48034100	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48034100	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48405675	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48405675	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48014713	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48014713	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	100000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	82000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3661000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	34989000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4909000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30135000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	56879000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	242000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3820000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	53301000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	53301000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	55000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	275000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4851000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	48780000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	48780000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8570000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8671000	usd
	us-gaap	Depreciation Depreciation	21000	usd
	us-gaap	Depreciation Depreciation	20000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-34000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	106000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38000	usd
	AIM	Increase Decreasein Rightof Use Assets IncreaseDecreaseinRightofUseAssets	48000	usd
	AIM	Increase Decreasein Rightof Use Assets IncreaseDecreaseinRightofUseAssets	-740000	usd
	AIM	Loss Gain From Sale Of Income Tax Operating Losses LossGainFromSaleOfIncomeTaxOperatingLosses	582000	usd
	AIM	Loss Gain From Sale Of Income Tax Operating Losses LossGainFromSaleOfIncomeTaxOperatingLosses	422000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	132000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	517000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	109000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1404000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1676000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1641000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-17000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	69000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-34000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	740000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	39000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	73000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1774000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	514000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-278000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	64000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5838000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5071000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	598000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	8713000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	712000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1262000	usd
	AIM	Proceeds From Payments To Purchase Of Property And Equipment ProceedsFromPaymentsToPurchaseOfPropertyAndEquipment	35000	usd
	AIM	Proceeds From Payments To Acquire Intangible Assets ProceedsFromPaymentsToAcquireIntangibleAssets	203000	usd
	AIM	Proceeds From Payments To Acquire Intangible Assets ProceedsFromPaymentsToAcquireIntangibleAssets	76000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-282000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7375000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	105000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	55000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	105000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6015000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2359000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27053000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32093000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21038000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34452000	usd
	AIM	Operating Leaseright Of Use Assets OperatingLeaserightOfUseAssets	-48000	usd
	AIM	Operating Leaseright Of Use Assets OperatingLeaserightOfUseAssets	761000	usd
	AIM	Unrealized Gain Loss On Marketable Securities UnrealizedGainLossOnMarketableSecurities	196000	usd
	AIM	Unrealized Gain Loss On Marketable Securities UnrealizedGainLossOnMarketableSecurities	-225000	usd
	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	6000	usd
	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	2000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	300000	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	132000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	517000	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	85000	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	454000	usd
CY2023Q2	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	7360000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	7137000	usd
CY2023Q2	us-gaap	Marketable Securities MarketableSecurities	7360000	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	7360000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	109000	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-87000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	196000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	7137000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	7137000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1679000	usd
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-751000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-928000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	36000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	313000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	492000	usd
CY2023Q2	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	97000	usd
CY2022Q4	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	110000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	82000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	203000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	528000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	806000	usd
	us-gaap	Depreciation Depreciation	21000	usd
	us-gaap	Depreciation Depreciation	20000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1800000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	133000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	161000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1974000	usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	375000	usd
CY2022	AIM	Finitelived Intangible Assets Abandonments FinitelivedIntangibleAssetsAbandonments	190000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	218000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1941000	usd
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	210000	usd
	AIM	Finitelived Intangible Assets Abandonments FinitelivedIntangibleAssetsAbandonments	7000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	106000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2038000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	108000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	212000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	205000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	203000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	183000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1127000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2038000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q2	AIM	Common Stock Shares With Limitations And Restrictions On Usage CommonStockSharesWithLimitationsAndRestrictionsOnUsage	8000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	264000	usd
CY2020Q1	AIM	Warrant Modifications WarrantModifications	46000	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15000	shares
CY2023Q2	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.030	pure
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	11937	shares
	AIM	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	5593	usd
CY2023Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.030	pure
CY2023Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	168	usd
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48419491	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48084287	shares
	AIM	Percentage Of Probability PercentageOfProbability	0.050	pure
	AIM	Floor Rate Used As Proxy For Future Volatility Percentage FloorRateUsedAsProxyForFutureVolatilityPercentage	1	pure
CY2023Q2	us-gaap	Derivative Assets DerivativeAssets	7360000	usd
CY2022Q4	us-gaap	Derivative Assets DerivativeAssets	7137000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P46M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P52M
	AIM	Percentage Of Incremental Borrowing Rate PercentageOfIncrementalBorrowingRate	0.10	pure
CY2022	AIM	Percentage Of Incremental Borrowing Rate PercentageOfIncrementalBorrowingRate	0.10	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	146000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	264000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	221000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	200000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	803000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	781000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	803000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	829000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	837000	usd
	us-gaap	Short Term Lease Payments ShortTermLeasePayments	141000	usd
	us-gaap	Short Term Lease Payments ShortTermLeasePayments	27000	usd

Files In Submission

Name	View Source	Status
aim-20230630_lab.xml	Edgar Link	unprocessable
aim-20230630_pre.xml	Edgar Link	unprocessable
0001493152-23-028610-index-headers.html	Edgar Link	pending
0001493152-23-028610-index.html	Edgar Link	pending
0001493152-23-028610.txt	Edgar Link	pending
0001493152-23-028610-xbrl.zip	Edgar Link	pending
aim-20230630.xsd	Edgar Link	pending
aim-20230630_cal.xml	Edgar Link	unprocessable
aim-20230630_def.xml	Edgar Link	unprocessable
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIM
AIM ImmunoTech Inc. Stock $aim

2023 Q3 Form 10-Q Financial Statement

#000149315223028610 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM AIM ImmunoTech Inc. Stock $aim

2023 Q3 Form 10-Q Financial Statement

#000149315223028610 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM
AIM ImmunoTech Inc. Stock $aim